Anti-Ro52/TRIM21 antibody-positive patients were more likely to be older (57.16 versus 54.98 years; P = 0.0481), to have interstitial lung disease (44% versus 34%; P = 0.0091), and to have overlap syndrome (22% versus 14%; P = 0.0059) compared with anti-Ro52/TRIM21 antibody-negative patients (Table 2). The gene discussed is TRIM21; the disease is overlapping connective tissue disease.